Real life results of ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Outcome from the German Ablation registry

Introduction: Ablation is a standard option in the treatment of atrial fibrillation (AF). Patients with AF and hypertrophic cardiomyopathy (HCM) may represent a more difficult substrate for AF ablation. Hypothesis: Is ablation AF in patients with HCM as successful as in patients with lone AF? Methods: Patient and procedural data as well as acute and long-term outcome data from pts. with ablation of AF were prospectively collected in 55 centres. One-year follow-up (1yFU) data were gathered by telephone call. Data collection and the statistical analysis were performed for the German Ablation Registry organized. Results: In total, 63 pts. with HCM (71% men, mean age 57y, 70% complete follow-up) and 4437 pts. without structural heart disease (65% men, mean age 61y, 59% complete follow-up) underwent ablation for AF. Pts. with HCM had additional coronary artery disease in 11%, valvular heart disease in 9.5% and a reduced ejection fraction (